Wells Fargo lowered the firm’s price target on Apellis (APLS) to $26 from $30 and keeps an Equal Weight rating on the shares. While Empa’s renal opportunities remain attractive, the firm remains on the sidelines until it sees Syfovre’s revenue outlook stabilize and gets more confident on Apellis’ ability to fund itself to profitability.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
- Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures
- Apellis Pharmaceuticals Reports Q1 2025 Financial Results
- Apellis Pharmaceuticals’ Earnings Call Highlights Achievements and Challenges
- Buy Rating Maintained for Apellis Pharmaceuticals Despite Short-Term Challenges